Wedbush Securities Inc Intellia Therapeutics, Inc. Transaction History

Wedbush Securities Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 21, 2022	SELL	$38.49 - $76.21 $125,400 - $248,292	-3,258 Closed	0 $0
Q1 2022 Apr 19, 2022	SELL	$58.27 - $118.99 $11,420 - $23,322	-196 Reduced 5.67%	3,258 $236,000
Q4 2021 Jan 13, 2022	BUY	$100.76 - $138.36 $705 - $968	7 Added 0.2%	3,454 $408,000
Q3 2021 Oct 08, 2021	SELL	$132.37 - $176.78 $52,153 - $69,651	-394 Reduced 10.26%	3,447 $462,000
Q2 2021 Jul 27, 2021	SELL	$60.88 - $161.91 $313,288 - $833,188	-5,146 Reduced 57.26%	3,841 $621,000
Q1 2021 Apr 26, 2021	BUY	$46.59 - $83.68 $418,704 - $752,032	8,987 New	8,987 $721,000

327

91.6M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $723M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.